Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.

Medicine --- immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley's Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma --- immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley's Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.

immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley’s Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma --- n/a --- Coley's Toxins

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a printed edition of the Special Issue Fungal Infections in Immunocompromised Hosts that was published in JoF

toxicity --- risk assessment --- species complex --- galactomannan --- taxonomy --- Aspergillus PCR --- candidemia --- adaptive immunity --- fungal immunity --- T2 Candida --- anti-fungal agents --- innate immunity --- antifungal stewardship --- Immunotherapy --- Candida meningoencephalitis --- liposomal amphotericin B --- anidulafungin --- liver disease --- invasive mold disease --- T2Candida --- AIDS --- (1?3)-?-d-glucan --- literature review --- yeast --- hepatic impairment --- prediction models --- IRIS --- invasive aspergillosis --- antifungal agent --- TNF inhibitors --- Aspergillus fumigatus --- fungal nomenclature --- micafungin --- non-culture-based diagnostics --- PCR --- paracoccidioidomycosis --- Candida auris --- multidrug resistance --- subcutaneous mycoses --- risk score --- mycoses of implantation --- Sporothrix brasiliensis --- antifungal resistance --- immunocompromised hosts --- Sporothrix schenckii --- Aspergillus --- fungus --- cell therapy --- MALDI-ToF MS --- lateral flow --- phylogenetics --- hematological malignancy --- candidiasis --- antifungal drug --- hematological malignancies --- mycoses --- invasive fungal infections --- lymphoma --- kidney transplant --- immune reconstitution inflammatory syndrome --- mechanisms of antifungal resistance --- fungal infections --- cytokine therapy --- sporotrichosis --- beta-d-glucan --- invasive fungal infection --- HIV --- cat-transmitted sporotrichosis --- aspergillosis --- cancer --- prognostic risk model

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nanobodies have become outstanding tools for biomedical research, diagnostics and therapy. Recent advances in the identification and functionalization of target-specific nanobodies now make nanobody-based approaches broadly available to many researches in the field. This book provides a compilation of original research articles and comprehensive reviews covering important and up to date aspects of research on nanobodies and their applications for immunoassays, proteomics, protein crystallization and in vitro and in vivo imaging.

Medicine --- Bacillus anthracis --- immunoassay --- single-domain antibody --- genetic fusion --- Beta galactosidase --- P-type ATPase --- nanobody --- llama --- Zinc-transport --- Zinc-transporting P-ATPase --- ZntA --- TNF --- fluorescent --- nanobodies --- sensor --- anti-cytokine therapy --- autoimmune disease --- Western equine encephalitis virus --- MagPlex --- toxin --- antibody --- camelid --- vaccine --- biodefense --- hydrogen exchange-mass spectrometry --- virus --- formatting --- Fc-domain --- half-life --- ischemia --- stroke --- MCAO --- single domain antibodies --- phage display --- intrabody --- intracellular antibody --- GTPase RHO --- BRET --- RAS --- chromobodies --- live-cell imaging --- compound screening --- cellular models --- single-domain antibody fragments --- molecular imaging --- molecular therapy --- nuclear imaging --- targeted fluorescence imaging --- intraoperative imaging --- Nanobody --- Single Domain Antibody --- Cancer --- Immunotherapy --- Imaging --- influenza --- influenza B virus --- hemagglutinin --- single domain antibody --- NanobodyTM --- yeast display --- epitope mapping --- GFP --- C. elegans --- development --- drosophila --- zebrafish --- targeted photodynamic therapy --- hepatocyte growth factor receptor --- HGFR --- c-Met --- Met --- VHH --- photosensitizer --- single-domain antibodies --- neurodegenerative diseases --- brain imaging --- blood-brain barrier --- delivery --- Aids --- HIV --- Llama Antibodies --- bi-specific VHH --- pepscan --- competition studies --- co-crystallisation --- Bacillus anthracis --- immunoassay --- single-domain antibody --- genetic fusion --- Beta galactosidase --- P-type ATPase --- nanobody --- llama --- Zinc-transport --- Zinc-transporting P-ATPase --- ZntA --- TNF --- fluorescent --- nanobodies --- sensor --- anti-cytokine therapy --- autoimmune disease --- Western equine encephalitis virus --- MagPlex --- toxin --- antibody --- camelid --- vaccine --- biodefense --- hydrogen exchange-mass spectrometry --- virus --- formatting --- Fc-domain --- half-life --- ischemia --- stroke --- MCAO --- single domain antibodies --- phage display --- intrabody --- intracellular antibody --- GTPase RHO --- BRET --- RAS --- chromobodies --- live-cell imaging --- compound screening --- cellular models --- single-domain antibody fragments --- molecular imaging --- molecular therapy --- nuclear imaging --- targeted fluorescence imaging --- intraoperative imaging --- Nanobody --- Single Domain Antibody --- Cancer --- Immunotherapy --- Imaging --- influenza --- influenza B virus --- hemagglutinin --- single domain antibody --- NanobodyTM --- yeast display --- epitope mapping --- GFP --- C. elegans --- development --- drosophila --- zebrafish --- targeted photodynamic therapy --- hepatocyte growth factor receptor --- HGFR --- c-Met --- Met --- VHH --- photosensitizer --- single-domain antibodies --- neurodegenerative diseases --- brain imaging --- blood-brain barrier --- delivery --- Aids --- HIV --- Llama Antibodies --- bi-specific VHH --- pepscan --- competition studies --- co-crystallisation